Tag: Lung cancer

AstraZeneca reports positive results for phase 2 COAST trial of oleclumab and monalizumab

businessnewstoday- September 18, 2021 0

AstraZeneca has reported positive results from the COAST phase 2 trial of its oleclumab or monalizumab in combination with Imfinzi (durvalumab) in patients with non-small ... Read More

Zydus Cadila gets FDA nod for chemotherapy drug Pemetrexed generic

businessnewstoday- June 28, 2021 0

Cadila Healthcare (also known as Zydus Cadila) said that it has secured tentative approval from the US Food and Drug Administration (FDA) for marketing Pemetrexed ... Read More

Amgen gets breakthrough therapy status for sotorasib in China

pharmanewsdaily- January 31, 2021 0

Amgen said that sotorasib, an investigational KRASG12C inhibitor, has been given breakthrough therapy designation (BTD) from the Center for Drug Evaluation (CDE) of the National ... Read More

AstraZeneca gets FDA approval for Tagrisso for type of NSCLC

pharmanewsdaily- December 19, 2020 0

AstraZeneca has secured extended approval from the US Food and Drug Administration for using Tagrisso (osimertinib) as an adjuvant treatment of non-small cell lung cancer ... Read More

BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC

pharmanewsdaily- November 8, 2020 0

Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small ... Read More

AstraZeneca strikes $6bn worth deal for Daiichi Sankyo’s DS-1062

pharmanewsdaily- July 27, 2020 0

AstraZeneca has signed a deal potentially worth up to $6 billion with Daiichi Sankyo for the global development and commercialization for the latter's DS-1062, a ... Read More

Selpercatinib FDA approval : Lilly’s therapy approved for treatment of lung and thyroid cancers with RET alteration

pharmanewsdaily- May 9, 2020 0

Selpercatinib FDA approval : The US Food and Drug Administration (FDA) has approved Eli Lilly and Company's Retevmo (selpercatinib) capsules for the treatment of three ... Read More

Genetron Health’s semiconductor-based NGS system gets Chinese approval

pharmanewsdaily- December 30, 2019 0

Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the ... Read More

Lilly launches LIBRETTO-431 clinical trial for selpercatinib in NSCLC

pharmanewsdaily- December 12, 2019 0

Eli Lilly and Company (Lilly) has initiated the phase 3 LIBRETTO-431 clinical trial to evaluate selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) ... Read More

Biodesix acquires Oncimmune’s laboratory and IPN malignancy test in US

pharmanewsdaily- November 4, 2019 0

Biodesix, a lung cancer diagnostic solutions company, has acquired UK-based Oncimmune’s laboratory and incidental pulmonary nodule (IPN) malignancy test in the US, to expand its ... Read More